☰

cached image

Stephen V Frye - Publications

Affiliations: 
UNC Eshelman School of Pharmacy University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Drug Discovery
Website:
https://pharmacy.unc.edu/news/directory/svfrye/
Tree Info Similar researchers PubMed Report error

86 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Cui G, Botuyan MV, Drané P, Hu Q, Bragantini B, Thompson JR, Schuller DJ, Detappe A, Perfetti MT, James LI, Frye SV, Chowdhury D, Mer G. An autoinhibited state of 53BP1 revealed by small molecule antagonists and protein engineering. Nature Communications. 14: 6091. PMID 37773238 DOI: 10.1038/s41467-023-41821-6  0.753
2023 Cui G, Botuyan MV, Drané P, Hu Q, Bragantini B, Thompson JR, Schuller DJ, Perfetti MT, James LI, Frye SV, Chowdhury D, Mer G. An autoinhibited state of 53BP1 revealed by chemical probes and protein engineering. Biorxiv : the Preprint Server For Biology. PMID 37131705 DOI: 10.1101/2023.04.20.534960  0.753
2021 Suh JL, Bsteh D, Hart B, Si Y, Weaver TM, Pribitzer C, Lau R, Soni S, Ogana H, Rectenwald JM, Norris JL, Cholensky SH, Sagum C, Umana JD, Li D, ... ... Frye SV, et al. Reprogramming CBX8-PRC1 function with a positive allosteric modulator. Cell Chemical Biology. PMID 34715055 DOI: 10.1016/j.chembiol.2021.10.003  0.317
2020 Puhl AC, Bogart JW, Haberman VA, Larson JE, Godoy AS, Norris-Drouin JL, Cholensky SH, Leisner TM, Frye SV, Parise LV, Bowers AA, Pearce KH. Discovery and Characterization of Peptide Inhibitors for CIB1. Acs Chemical Biology. PMID 32383857 DOI: 10.1021/Acschembio.0C00144  0.355
2020 Rectenwald JM, Guduru SKR, Dang Z, Collins LB, Liao YE, Norris-Drouin JL, Cholensky SH, Kaufmann KW, Hammond SM, Kireev DB, Frye SV, Pearce KH. Design and Construction of a Focused DNA-Encoded Library for Multivalent Chromatin Reader Proteins. Molecules (Basel, Switzerland). 25. PMID 32098353 DOI: 10.3390/Molecules25040979  0.391
2020 Barnes DE, Wang X, Frye SV, Earp HS, DeRyckere D, Barnes DK. Abstract 6388: MERTK and ROCK inhibitors mediate synergistic AML cell death and enhance therapeutic activity in combination with cytotoxic chemotherapy Cancer Research. 80: 6388-6388. DOI: 10.1158/1538-7445.Am2020-6388  0.353
2020 Yan D, Huelse J, Parker R, Tan Z, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract 1882: MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib Cancer Research. 80: 1882-1882. DOI: 10.1158/1538-7445.Am2020-1882  0.341
2020 Maffuid KA, Torrice CD, Hardy B, Murphy WA, James LI, Kim WY, Frye SV, Pearce KJ, Crona DJ. Abstract 1743: Evaluation of the effects of combined chemical inhibition of PARP and BET proteins in preclinical models of urothelial bladder cancer Cancer Research. 80: 1743-1743. DOI: 10.1158/1538-7445.Am2020-1743  0.383
2019 Foley CA, Potjewyd F, Lamb KN, James LI, Frye SV. Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay. Acs Chemical Biology. PMID 31846298 DOI: 10.1021/Acschembio.9B00972  0.36
2019 Da C, Zhang D, Stashko M, Vasileiadi E, Parker R, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, ... ... Frye SV, et al. Data-driven construction of anti-tumor agents with controlled polypharmacology. Journal of the American Chemical Society. PMID 31497954 DOI: 10.1021/Jacs.9B08660  0.373
2019 Holtzhausen A, Harris W, Ubil E, Hunter DM, Zhao J, Zhang Y, Zhang D, Liu Q, Wang X, Graham DK, Frye SV, Earp HS. TAM Family Receptor kinase inhibition reverses MDSC-mediated suppression and augments anti-PD-1 therapy in melanoma. Cancer Immunology Research. PMID 31451482 DOI: 10.1158/2326-6066.Cir-19-0008  0.333
2019 Lamb KN, Bsteh D, Dishman SN, Moussa HF, Fan H, Stuckey JI, Norris JL, Cholensky SH, Li D, Wang J, Sagum C, Stanton BZ, Bedford MT, Pearce KH, Kenakin TP, ... ... Frye SV, et al. Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7. Cell Chemical Biology. PMID 31422906 DOI: 10.1016/J.Chembiol.2019.07.013  0.394
2019 Wong JP, Stuhlmiller TJ, Giffin LC, Lin C, Bigi R, Zhao J, Zhang W, Bravo Cruz AG, Park SI, Earp HS, Dittmer DP, Frye SV, Wang X, Johnson GL, Damania B. Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31346082 DOI: 10.1073/Pnas.1903991116  0.327
2019 Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, Huang D, Whiten GC, Larson JE, Wang X, Pearce KH, Herring LE, Graves LM, Frye SV, Emanuele MJ, et al. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Science Signaling. 12. PMID 31311847 DOI: 10.1126/Scisignal.Aav7259  0.349
2019 Moussa HF, Bsteh D, Yelagandula R, Pribitzer C, Stecher K, Bartalska K, Michetti L, Wang J, Zepeda-Martinez JA, Elling U, Stuckey JI, James LI, Frye SV, Bell O. Canonical PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing. Nature Communications. 10: 1931. PMID 31036804 DOI: 10.1038/S41467-019-09628-6  0.325
2019 Suh JL, Barnash KD, Abramyan TM, Li F, The J, Engelberg IA, Vedadi M, Brown PJ, Kireev DB, Arrowsmith CH, James LI, Frye SV. Discovery of selective activators of PRC2 mutant EED-I363M. Scientific Reports. 9: 6524. PMID 31024026 DOI: 10.1038/S41598-019-43005-Z  0.322
2019 Gu C, Stashko MA, Puhl-Rubio A, Chakraborty M, Chakraborty A, Frye SV, Pearce KH, Wang X, Shears SB, Wang H. Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure/Activity Analysis. Journal of Medicinal Chemistry. PMID 30624931 DOI: 10.2210/Pdb6M8D/Pdb  0.36
2019 Yan D, Huelse J, Parker R, Wang X, Frye SV, Earp HS, DeRyckere D, Graham D. Abstract 4765: MERTK is a potential therapeutic target in osimertinib-resistant non-small cell lung cancer Cancer Research. 79: 4765-4765. DOI: 10.1158/1538-7445.Sabcs18-4765  0.355
2019 Summers RJ, Minson KA, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract A35: MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-A35  0.315
2019 Minson KA, Vasileiadi E, Huey MG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract 3037: Stromal cell activation of MAPK signaling pathways mediates resistance to MERTK inhibition in acute myeloid leukemia Cancer Research. 79: 3037-3037. DOI: 10.1158/1538-7445.Am2019-3037  0.327
2018 Hopcraft SE, Pattenden SG, James LI, Frye S, Dittmer DP, Damania B. Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. Plos Pathogens. 14: e1007267. PMID 30212584 DOI: 10.1371/Journal.Ppat.1007267  0.379
2018 Yan D, Parker RE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. MERTK promotes resistance to irreversible EGFR tyrosine kinase inhibitors in non-small cell lung cancers expressing wild-type EGFR-family members. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30194074 DOI: 10.1158/1078-0432.Ccr-18-0040  0.314
2018 Suh JL, Watts B, Stuckey JI, Norris-Drouin JL, Cholensky SH, Dickson BM, An Y, Mathea S, Salah E, Knapp S, Khan A, Adams AT, Strahl BD, Sagum CA, Bedford MT, ... ... Frye SV, et al. Quantitative characterization of bivalent probes for a dual bromodomain protein, Transcription Initiation Factor TFIID subunit 1, TAF1. Biochemistry. PMID 29558110 DOI: 10.1021/Acs.Biochem.8B00150  0.335
2018 McDaniel NK, Cummings CT, Brand TM, Iida M, Hulse J, Pearson HE, Orbuch RA, Ondracek OJ, Davies KD, Gill P, Wang X, Frye SV, Earp HS, Kimple RJ, Harari PM, et al. Abstract A140: MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A140  0.373
2017 Yan D, Wang X, Frye SV, Earp SH, DeRyckere D, Graham DK. Abstract 1082: MerTK promotes resistance to irreversible EGFR TKIs by activation of the PI3K-AKT pathway in NSCLCs expressing wild-type EGFR Cancer Research. 77: 1082-1082. DOI: 10.1158/1538-7445.Am2017-1082  0.348
2017 Barnash KD, Lamb KN, James LI, Frye SV. Peptide Technologies in the Development of Chemical Tools for Chromatin-Associated Machinery Drug Development Research. 78: 300-312. DOI: 10.1002/Ddr.21398  0.374
2016 Baughman BM, Wang H, An Y, Kireev D, Stashko MA, Jessen HJ, Pearce KH, Frye SV, Shears SB. A High-Throughput Screening-Compatible Strategy for the Identification of Inositol Pyrophosphate Kinase Inhibitors. Plos One. 11: e0164378. PMID 27736936 DOI: 10.1371/Journal.Pone.0164378  0.357
2016 Page LS, Wang X, Earp HS, Frye S, Jordan CT, Lee-Sherick AB. MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia Blood. 128: 4044-4044. DOI: 10.1182/Blood.V128.22.4044.4044  0.309
2016 Minson KA, Huey MG, Hill AA, Perez I, Wang X, Frye S, Earp HS, DeRyckere D, Graham DK. Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia Blood. 128: 2819-2819. DOI: 10.1182/Blood.V128.22.2819.2819  0.315
2015 Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, et al. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget. 6: 6722-36. PMID 25762638 DOI: 10.18632/Oncotarget.3156  0.352
2015 Da C, Stashko M, Jayakody C, Wang X, Janzen W, Frye S, Kireev D. Discovery of Mer kinase inhibitors by virtual screening using Structural Protein-Ligand Interaction Fingerprints. Bioorganic & Medicinal Chemistry. 23: 1096-101. PMID 25638502 DOI: 10.1016/J.Bmc.2015.01.001  0.376
2015 Perfetti MT, Baughman BM, Dickson BM, Mu Y, Cui G, Mader P, Dong A, Norris JL, Rothbart SB, Strahl BD, Brown PJ, Janzen WP, Arrowsmith CH, Mer G, McBride KM, ... ... Frye SV, et al. Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1. Acs Chemical Biology. 10: 1072-81. PMID 25590533 DOI: 10.1021/Cb500956G  0.757
2015 Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, Allison DF, Cai L, Rockowitz S, Liu S, Liu Y, Li F, Vedadi M, Frye SV, Garcia BA, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 125: 346-57. PMID 25395428 DOI: 10.1182/Blood-2014-06-581082  0.434
2015 James LI, Stuckey JI, Baughman BM, Perfetti MT, Pattenden SG, Dickson BM, Norris JL, Cui G, Mader P, Dong A, Mu Y, Rothbart SB, Strahl BD, Min J, Brown PJ, ... ... Frye SV, et al. Abstract SY08-03: Targeting chromatin regulation for cancer therapy: progress towards chemical probes for methyl-lysine readers Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Sy08-03  0.752
2015 Graham D, DeRyckere D, Minson K, Smith C, Hill A, Huey M, Lasater E, Wang X, Shah N, Frye S, Shelton Earp H. Development of novel small molecule MerTK and Flt3 tyrosine kinase inhibitors for treatment of acute leukemia Annals of Oncology. 26: ii6. DOI: 10.1093/Annonc/Mdv082.2  0.367
2014 Ma A, Yu W, Li F, Bleich RM, Herold JM, Butler KV, Norris JL, Korboukh V, Tripathy A, Janzen WP, Arrowsmith CH, Frye SV, Vedadi M, Brown PJ, Jin J. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. Journal of Medicinal Chemistry. 57: 6822-33. PMID 25032507 DOI: 10.1021/Jm500871S  0.4
2014 DeRyckere D, Lee-Sherick AB, Hill AA, Page L, Wang X, Frye SV, Earp HS, Graham DK. UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft Models of Acute Leukemia Blood. 124: 998-998. DOI: 10.1182/Blood.V124.21.998.998  0.356
2014 Minson KA, Smith CC, Lee-Sherick AB, DeRyckere D, Lasater E, Hill AA, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia Blood. 124: 3757-3757. DOI: 10.1182/Blood.V124.21.3757.3757  0.356
2014 Graham DK, DeRyckere D, Lee-Sherick A, Hill AA, Minson K, Xiaodong W, Zhang W, Liu J, Frye S, Earp HS. Abstract A37: MerTK receptor tyrosine kinase is a therapeutic target in pediatric acute leukemia Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A37  0.358
2014 Earp HS, Darr D, Zimmermann A, Clark K, Sharpless NE, Bergmeier W, Zhang W, Wang X, DeRyckere D, Frye S, Graham D. Abstract 947: A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma Cancer Research. 74: 947-947. DOI: 10.1158/1538-7445.Am2014-947  0.376
2014 Teodorovic LS, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Eckhardt SG, Earp HS, Graham DK. Abstract 730: Efficacy of a novel small molecule MER receptor tyrosine kinase inhibitor in B-RAF wild-type and B-RAF mutant melanoma cell lines Cancer Research. 74: 730-730. DOI: 10.1158/1538-7445.Am2014-730  0.34
2014 Fer ND, Harris E, Fox S, Zhou M, Simpson C, Liu J, Korboukh I, Hull-Ryde EA, Janzen WP, Frye SV, Monks A, Teicher B, Rapisarda A. Abstract 3741: Development and characterization of a cell based assay for the validation of mutant IDH1 inhibitors Cancer Research. 74: 3741-3741. DOI: 10.1158/1538-7445.Am2014-3741  0.367
2014 Jacobsen KM, DeRyckere D, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. Abstract 3637: Targeted inhibition of MER tyrosine kinase in the tumor microenvironment decreases tumor growth in a mouse model of breast cancer Cancer Research. 74: 3637-3637. DOI: 10.1158/1538-7445.Am2014-3637  0.304
2014 Sherick AL, Menachof K, Hill A, Rinella S, DeRyckere D, Liu J, Wang X, Frye S, Earp HS, Graham D. Abstract 1743: A dual FLT-3 and MER tyrosine kinase small molecule inhibitor in acute myeloid leukemia cell lines and patient samples Cancer Research. 74: 1743-1743. DOI: 10.1158/1538-7445.Am2014-1743  0.351
2014 Cummings CT, Davies KD, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Graham DK. Abstract 1742: Inhibition of Mer tyrosine kinase with a novel small molecule inhibitor is efficacious in pre-clinical models of non-small cell lung cancer Cancer Research. 74: 1742-1742. DOI: 10.1158/1538-7445.Am2014-1742  0.377
2014 DeRyckere DA, Hill AA, Wang X, Zhang W, Stashko MA, Sather S, Cummings C, Kireev D, Janzen WP, Frye SV, Earp HS, Graham DK. Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia Cancer Research. 74: 1740-1740. DOI: 10.1158/1538-7445.Am2014-1740  0.399
2014 Newton TP, Cummings CT, Kirkpatrick GD, Hinz TK, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Heasley L, Graham DK. Abstract 1736: A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition Cancer Research. 74: 1736-1736. DOI: 10.1158/1538-7445.Am2014-1736  0.38
2014 Wu J, Huey L, Bash RE, Cohen SM, Ewend MG, Wang X, Graham DK, Frye SV, Earp HS, Miller CR. NT-38 * MerTK AS A TARGET IN GLIOBLASTOMA Neuro-Oncology. 16: v166-v167. DOI: 10.1093/Neuonc/Nou265.36  0.319
2014 Liu J, Yang C, Simpson C, DeRyckere D, Deusen AV, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, ... ... Frye SV, et al. Correction to Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia Acs Medicinal Chemistry Letters. 5: 1173-1173. DOI: 10.1021/Ml500328M  0.314
2014 Earp S, Darr D, Holtzhausen A, Zimmermann A, Clark K, Hunter L, Sharpless N, Wang X, Frye S, Graham D. 503 UNC2025: A small molecule inhibitor of merTK with efficacy in mouse melanoma models European Journal of Cancer. 50: 164. DOI: 10.1016/S0959-8049(14)70629-X  0.32
2014 Graham D, DeRyckere D, Wang X, Hill A, Zhang W, Frye S, Earp H. 352 UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute leukemia European Journal of Cancer. 50: 114. DOI: 10.1016/S0959-8049(14)70478-2  0.341
2013 Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, ... ... Frye SV, et al. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry. 56: 9693-700. PMID 24219778 DOI: 10.1021/Jm501217P  0.357
2013 Liu F, Barsyte-Lovejoy D, Li F, Xiong Y, Korboukh V, Huang XP, Allali-Hassani A, Janzen WP, Roth BL, Frye SV, Arrowsmith CH, Brown PJ, Vedadi M, Jin J. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. Journal of Medicinal Chemistry. 56: 8931-42. PMID 24102134 DOI: 10.1021/Jm401480R  0.343
2013 James LI, Korboukh VK, Krichevsky L, Baughman BM, Herold JM, Norris JL, Jin J, Kireev DB, Janzen WP, Arrowsmith CH, Frye SV. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. Journal of Medicinal Chemistry. 56: 7358-71. PMID 24040942 DOI: 10.1021/jm400919p  0.306
2013 Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, ... ... Frye SV, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics. 12: 2367-77. PMID 23997116 DOI: 10.1158/1535-7163.Mct-13-0040  0.372
2013 Lee-Sherick AB, Menachof K, Hill AA, Rinella S, Liu J, DeRyckere D, Wang X, Frye SV, Earp HS, Graham DK. UNC1666, a Dual Mer and Flt-3 Tyrosine Kinase Small Molecule Inhibitor In Acute Myeloid Leukemia Blood. 122: 3849-3849. DOI: 10.1182/Blood.V122.21.3849.3849  0.354
2013 Acevedo G, Branchford BR, Law L, Brzezinski C, Sather S, Brodsky G, DeRyckere D, Zhang W, Earp HS, Frye SV, Graham DK, Di Paola J. Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Mediate Synergistic Inhibition Of Platelet Aggregation In Combination With ADP/P2Y Antagonists Blood. 122: 3507-3507. DOI: 10.1182/Blood.V122.21.3507.3507  0.312
2013 DeRyckere D, Wang X, Hill AA, Zhang W, Stashko MA, Sather S, Cummings CE, Janzen WP, Frye SV, Earp HS, Graham DK. Development Of a Novel Small Molecule Inhibitor Of The Mer Tyrosine Kinase For Treatment Of Acute Lymphoblastic Leukemia Blood. 122: 2666-2666. DOI: 10.1182/Blood.V122.21.2666.2666  0.369
2013 Acevedo G, Branchford BR, Brzezinski C, Sather S, Brodsky G, DeRyckere D, Zhang W, Liu J, Earp HS, Wang X, Frye SV, Graham DK, Di Paola J. Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Inhibit Platelet Aggregation In Vitro and Protect Mice From Arterial and Venous Thrombosis In Vivo Blood. 122: 2296-2296. DOI: 10.1182/Blood.V122.21.2296.2296  0.3
2013 Christoph S, Maag S, DeRyckere D, Graham DK, Frye SV, Earp HS, Liu J, Yang C, Zhang W, Wang X, Elmaagacli AH, Beelen D. Mer Receptor Tyrosine Kinase Is a Novel Therapeutic Target In Multiple Myeloma Blood. 122: 1957-1957. DOI: 10.1182/Blood.V122.21.1957.1957  0.343
2013 Schlegel J, Sambade M, Sather S, Moschos S, Tan A, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt G, Kuan P, Hamilton RL, Duncan LM, Miller CR, ... ... Frye SV, et al. Abstract 3037: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma. Cancer Research. 73: 3037-3037. DOI: 10.1158/1538-7445.Am2013-3037  0.359
2012 Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, Frye SV, Wetsel WC, Roth BL, Jin J. Structure-functional selectivity relationship studies of β-arrestin-biased dopamine Dâ‚‚ receptor agonists. Journal of Medicinal Chemistry. 55: 7141-53. PMID 22845053 DOI: 10.1021/Jm300603Y  0.303
2012 Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, ... ... Frye SV, et al. Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. Acs Medicinal Chemistry Letters. 3: 129-134. PMID 22662287 DOI: 10.1021/Ml200239K  0.362
2012 Christoph S, DeRyckere D, Schlegel J, Sather S, McGranahan A, Franzer JK, Trakhimets A, Wang X, Kireev D, Janzen W, Liu J, Yang C, Simpson C, Norris-Drouin J, Frye S, et al. Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo. Blood. 120: 2607-2607. DOI: 10.1182/Blood.V120.21.2607.2607  0.35
2012 Lee-Sherick AB, Menachof K, Eisenman KM, McGranahan A, McGary C, Hunsucker SA, Schlegel J, Armistead PM, Liang X, Kireev D, Janzen W, Liu J, Stashko M, Norris-Drouin J, Earp HS, ... ... Frye S, et al. Mer Receptor Tyrosine Kinase Is A Potential Therapeutic Target in Acute Myeloid Leukemia Blood. 120: 1317-1317. DOI: 10.1182/Blood.V120.21.1317.1317  0.352
2011 Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, ... Frye S, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 19: 17-30. PMID 21251613 DOI: 10.1016/J.Ccr.2010.12.014  0.346
2011 Christoph S, DeRyckere D, Sather S, Wang X, Kireev D, Janzen W, Liu J, Yang C, van Deusen A, Simpson C, Norris-Drouin J, Frye S, Earp HS, Johnson GL, Graham DK. UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL Blood. 118: 2589-2589. DOI: 10.1182/Blood.V118.21.2589.2589  0.354
2010 Liu F, Chen X, Allali-Hassani A, Quinn AM, Wigle TJ, Wasney GA, Dong A, Senisterra G, Chau I, Siarheyeva A, Norris JL, Kireev DB, Jadhav A, Herold JM, Janzen WP, ... ... Frye SV, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. Journal of Medicinal Chemistry. 53: 5844-57. PMID 20614940 DOI: 10.1021/Jm100478Y  0.315
2010 Wigle TJ, Herold JM, Senisterra GA, Vedadi M, Kireev DB, Arrowsmith CH, Frye SV, Janzen WP. Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins. Journal of Biomolecular Screening. 15: 62-71. PMID 20008125 DOI: 10.1177/1087057109352902  0.39
2010 CHEN X, HORTELANO ER, ELIEL EL, FRYE SV. ChemInform Abstract: Chelates as Intermediates in Nucleophilic Additions to Alkoxy Ketones According to Cram′s Rule (Cyclic Model). Cheminform. 23: no-no. DOI: 10.1002/chin.199226065  0.41
2003 Eliel EL, Lynch JE, Kume F, Frye SV. Chiral 1,3‐Oxathiane from (+)‐Pulegone: Hexahydro‐4,4,7‐trimethyl‐4H‐1,3‐benzoxathiin Organic Syntheses. 215-215. DOI: 10.1002/0471264180.Os065.26  0.484
1992 Chen X, Hortelano ER, Eliel EL, Frye SV. Chelates as intermediates in nucleophilic additions to alkoxy ketones according to Cram's rule (cyclic model) Journal of the American Chemical Society. 114: 1778-1784. DOI: 10.1021/Ja00031A036  0.415
1991 Eliel EL, Frye SV, Hortelano ER, Chen X, Bai X. Asymmetric synthesis and cram's (chelate) rule Pure and Applied Chemistry. 63: 1591-1598. DOI: 10.1351/Pac199163111591  0.45
1990 Chen X, Hortelano ER, Eliel EL, Frye SV. Are chelates truly intermediates in Cram's chelate rule? Journal of the American Chemical Society. 112: 6130-6131. DOI: 10.1021/Ja00172A040  0.396
1990 CHEN X, HORTELANO ER, ELIEL EL, FRYE SV. ChemInform Abstract: Are Chelates Truly Intermediates in Cram′s Chelate Rule? Cheminform. 21. DOI: 10.1002/chin.199047079  0.4
1988 Frye SV, Eliel EL. Asymmetric synthesis based on 1,3-oxathianes. 4. Mechanism of asymmetric induction in the reactions of oxathianyl ketones Journal of the American Chemical Society. 110: 484-489. DOI: 10.1021/Ja00210A028  0.452
1988 FRYE SV, ELIEL EL. ChemInform Abstract: Asymmetric Synthesis Based on 1,3-Oxathianes. Part 4. Mechanism of Asymmetric Induction in the Reactions of Oxathianyl Ketones. Cheminform. 19. DOI: 10.1002/chin.198818216  0.408
1987 Frye SV, Eliel EL, Cloux R. Rapid-injection nuclear magnetic resonance investigation of the reactivity of .alpha.- and .beta.-alkoxy ketones with dimethylmagnesium: kinetic evidence for chelation Journal of the American Chemical Society. 109: 1862-1863. DOI: 10.1021/Ja00240A047  0.43
1987 FRYE SV, ELIEL EL, CLOUX R. ChemInform Abstract: Rapid-Injection NMR Investigation of the Reactivity of α- and β-Alkoxy Ketones with Dimethylmagnesium: Kinetic Evidence for Chelation. Cheminform. 18. DOI: 10.1002/chin.198730135  0.386
1986 Frye SV, Eliel EL. Prevention of chelation by an oxygen function through protection with a triisopropyl silyl group Tetrahedron Letters. 27: 3223-3226. DOI: 10.1016/S0040-4039(00)84759-0  0.46
1986 FRYE SV, ELIEL EL. ChemInform Abstract: Prevention of Chelation by an Oxygen Function through Protection with a Triisopropyl Silyl Group. Chemischer Informationsdienst. 17. DOI: 10.1002/chin.198649130  0.382
1986 FRYE SV, ELIEL EL. ChemInform Abstract: Asymmetric Chemical Synthesis of (R)- and (S)-Citramalate in High Enantiomeric Purity. Chemischer Informationsdienst. 17. DOI: 10.1002/chin.198627078  0.429
1986 FRYE SV, ELIEL EL. ChemInform Abstract: Nonenzymatic Asymmetric Synthesis of (R)-(-)- and (S)-(+)-Mevalolactone in High Enantiomeric Purity. Chemischer Informationsdienst. 17. DOI: 10.1002/chin.198602195  0.42
1985 Frye SV, Eliel EL. Aymmetric synthesis of (R) - and (S)-citramalate in high enantiomeric purity Tetrahedron Letters. 26: 3907-3910. DOI: 10.1016/S0040-4039(00)98684-2  0.484
1985 Frye SV, Eliel EL. Nonenzymatic asymmetric synthesis of (R)-(-)-and (S)-(+)-mevalolactone in high enantiomeric purity Journal of Organic Chemistry. 50: 3402-3404. DOI: 10.1002/Chin.198602195  0.478
1985 FRYE SV, ELIEL EL. ChemInform Abstract: Asymmetric Synthesis of (R)- and (S)-Citramalate in High Enantiomeric Purity. Chemischer Informationsdienst. 16. DOI: 10.1002/chin.198550115  0.42
Show low-probability matches.